0AG0 logo

0AG0 (0AG0)

Market Closed
15 Oct, 06:05 AM
XFRA XFRA
€
0. 06
-0
-0.1669%
€
33.72M Market Cap
- P/E Ratio
- Div Yield
4,000 Volume
- Eps
€ 0.06
Previous Close
Add Transaction
Day Range
0.06 0.06
Year Range
0.05 0.21
Want to track 0AG0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0AG0 closed yesterday lower at €0.06, a decrease of -0.1669% from Wednesday's close, completing a monthly decrease of -11.7994% or -€0.01. Over the past 12 months, 0AG0 stock lost -37.0526%.
0AG0 is not paying dividends to its shareholders.
0AG0 has completed 1 stock splits, with the recent split occurring on Mar 27, 2026.
The company's stock is traded on one exchange.

0AG0 Chart

People also search for

DCV
Advanex Inc.
€ 16.6
+1.8405%
OKYO Pharma Limited
€ 1.36
0%
3NQ
Nano mRNA Co., Ltd.
€ 0.47
+13.0435%
78W
Modulight Oyj
€ 0.94
0%
PGT
StrongPoint ASA
€ 0.87
+2.1127%

0AG0 (0AG0) FAQ

What is the stock price today?

The current price is €0.06.

On which exchange is it traded?

0AG0 is listed on XFRA.

What is its stock symbol?

The ticker symbol is 0AG0.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 33.72M.

Has 0AG0 ever had a stock split?

0AG0 had 1 splits and the recent split was on Mar 27, 2026.

0AG0 Profile

Biotechnology Industry
Healthcare Sector
Mr. Sridhar Vempati MBA, Ph.D. CEO
XFRA Exchange
- ISIN
United Kingdom Country
7 Employees
- Last Dividend
27 Mar 2026 Last Split
- IPO Date

Overview

Coiled Therapeutics plc is a clinical-stage biotechnology firm dedicated to the advancement of precision oncology medicines aimed at addressing challenging cancer types. The company primarily focuses on targeted therapies that can effectively treat aggressive solid tumors, with a particular interest in innovative small-molecule solutions that are suitable for oral intake and can penetrate the central nervous system. Coiled Therapeutics plc's current pipeline comprises oncology programs under early-stage clinical evaluation, wherein the key aspects of safety, tolerability, and biological activity are thoroughly assessed in patients suffering from advanced disease. Situated within the wider life sciences sector, Coiled Therapeutics plc plays an essential role in promoting precision medicine and biomarker-driven drug development in the realm of cancer treatment. With a commitment to tackling complex oncology challenges, the company is poised to develop specialized therapeutic options that meet considerable unmet medical needs. Coiled Therapeutics plc is headquartered in London and is steadfastly focused on propelling experimental cancer therapies through the necessary clinical development phases.

Products and Services

  • Targeted Therapies: Coiled Therapeutics plc specializes in the creation of targeted therapies that aim to selectively attack cancer cells, while minimizing damage to healthy tissues. These therapies are designed to enhance the effectiveness of treatment regimens for patients suffering from aggressive solid tumors.
  • Small-Molecule Approaches: The company emphasizes the development of novel small-molecule drugs that can be administered orally and possess the ability to penetrate the central nervous system. These innovative approaches are vital in addressing complex tumor types that are typically difficult to treat.
  • Clinical Trials: Coiled Therapeutics plc is actively engaged in early-phase clinical studies to evaluate the safety, tolerability, and biological activity of its oncology programs. This data is crucial for understanding the potential effectiveness of its therapies.
  • Precision Medicine: By utilizing precision medicine strategies, the company aims to identify specific biomarkers that can inform treatment plans, thereby enhancing the probability of successful outcomes for patients with hard-to-treat cancers.
  • Oncology Programs: Coiled Therapeutics plc’s pipeline is specifically focused on oncology programs that are in the early stages of clinical development, highlighting the company's commitment to addressing significant unmet medical need in cancer care.

Contact Information

Address: 85 Great Portland Street
Phone: 44 20 3918 8633